{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:50:57Z","timestamp":1780487457595,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00108-025-01884-7","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T06:18:04Z","timestamp":1747376284000},"page":"603-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Diagnostik und Therapie der Osteoporose im Jahr 2025","Diagnostics and treatment of osteoporosis in 2025"],"prefix":"10.1007","volume":"66","author":[{"given":"Philipp","family":"Klemm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"B\u00fchring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"1","key":"1884_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis\u00a0JA, Norton\u00a0N, Harvey\u00a0NC, Jacobson\u00a0T, Johansson\u00a0H, Lorentzon\u00a0M et\u00a0al (2021) SCOPE 2021: a\u00a0new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):1\u201382. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"issue":"S16","key":"1884_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00508-024-02441-2","volume":"136","author":"HP Dimai","year":"2024","unstructured":"Dimai\u00a0HP, Muschitz\u00a0C, Amrein\u00a0K, Bauer\u00a0R, Cejka\u00a0D, Gasser\u00a0RW et\u00a0al (2024) Osteoporose \u2013 Definition, Risikoerfassung, Diagnose, Pr\u00e4vention und Therapie (Update 2024). Wien Klin Wochenschr 136(S16):599\u2013668. https:\/\/doi.org\/10.1007\/s00508-024-02441-2","journal-title":"Wien Klin Wochenschr"},{"key":"1884_CR3","volume-title":"DVO-Leitlinie-zur-Diagnostik-und-Therapie-der-Osteoporose-Version-2.1.-2023-002","author":"F Thomasius","year":"2023","unstructured":"Thomasius\u00a0F (2023) DVO-Leitlinie-zur-Diagnostik-und-Therapie-der-Osteoporose-Version\u20112.1.-2023-002. AWMF (Register-Nr: 183\/001 2023)"},{"issue":"1","key":"1884_CR4","doi-asserted-by":"publisher","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","volume":"2","author":"R Eastell","year":"2016","unstructured":"Eastell\u00a0R, O\u2019Neill\u00a0TW, Hofbauer\u00a0LC, Langdahl\u00a0B, Reid\u00a0IR, Gold\u00a0DT et\u00a0al (2016) Postmenopausal osteoporosis. Nat Rev Dis Primers 2(1):16069","journal-title":"Nat Rev Dis Primers"},{"key":"1884_CR5","doi-asserted-by":"publisher","first-page":"965258","DOI":"10.3389\/fendo.2022.965258","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang\u00a0W, Gao\u00a0R, Rong\u00a0X, Zhu\u00a0S, Cui\u00a0Y, Liu\u00a0H et\u00a0al (2022) Immunoporosis: role of immune system in the pathophysiology of different types of osteoporosis. Front Endocrinol 13:965258","journal-title":"Front Endocrinol"},{"issue":"4","key":"1884_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00198-003-1525-x","volume":"15","author":"S Cvijeti\u0107","year":"2004","unstructured":"Cvijeti\u0107\u00a0S, Kor\u0161i\u0107\u00a0M (2004) Apparent bone mineral density estimated from DXA in healthy men and women. Osteoporos Int 15(4):295\u2013300","journal-title":"Osteoporos Int"},{"key":"1884_CR7","isbn-type":"print","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-64207-8","volume-title":"Osteoporose in der Praxis","author":"R Bartl","year":"2022","unstructured":"Bartl\u00a0R (2022) Osteoporose in der Praxis. Springer Nature. ISBN 978-3-662-64207\u20118.","ISBN":"https:\/\/id.crossref.org\/isbn\/9783662642078"},{"issue":"1","key":"1884_CR8","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC202401160","volume":"177","author":"KE Ensrud","year":"2024","unstructured":"Ensrud\u00a0KE, Crandall\u00a0CJ (2024) Osteoporosis. Ann Intern Med 177(1):ITC1\u201316","journal-title":"Ann Intern Med"},{"key":"1884_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00508-024-02441-2","volume":"136","author":"HP Dimai","year":"2024","unstructured":"Dimai\u00a0HP, Muschitz\u00a0C, Amrein\u00a0K, Bauer\u00a0R, Cejka\u00a0D, Gasser\u00a0RW et\u00a0al (2024) Osteoporose \u2013 Definition, Risikoerfassung, Diagnose, Pr\u00e4vention und Therapie (Update 2024) : Leitlinie der \u00d6sterreichischen Gesellschaft f\u00fcr Knochen- und Mineralstoffwechsel. Wien Klin Wochenschr 136:599\u2013668","journal-title":"Wien Klin Wochenschr"},{"key":"1884_CR10","unstructured":"Kanis JA (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. http:\/\/www.shef ac.uk\/FRAX"},{"key":"1884_CR11","unstructured":"WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7941614. Zugegriffen: 19. Dez. 2024"},{"issue":"4","key":"1884_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis\u00a0JA, Burlet\u00a0N, Cooper\u00a0C, Delmas\u00a0PD, Reginster\u00a0JY, Borgstrom\u00a0F et\u00a0al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399","journal-title":"Osteoporos Int"},{"issue":"7041","key":"1884_CR13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall\u00a0D, Johnell\u00a0O, Wedel\u00a0H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254\u20131259","journal-title":"BMJ"},{"issue":"1","key":"1884_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S8756-3282(01)00653-6","volume":"30","author":"JA Kanis","year":"2002","unstructured":"Kanis\u00a0JA, Johnell\u00a0O, Oden\u00a0A, De Laet\u00a0C, Jonsson\u00a0B, Dawson\u00a0A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30(1):251\u2013258","journal-title":"Bone"},{"issue":"10","key":"1884_CR15","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris\u00a0ES, Chen\u00a0YT, Abbott\u00a0TA, Barrett-Connor\u00a0E, Miller\u00a0PD, Wehren\u00a0LE et\u00a0al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108\u20131112","journal-title":"Arch Intern Med"},{"issue":"6","key":"1884_CR16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00198-019-05274-2","volume":"31","author":"WD Leslie","year":"2020","unstructured":"Leslie\u00a0WD, Schousboe\u00a0JT, Morin\u00a0SN, Martineau\u00a0P, Lix\u00a0LM, Johansson\u00a0H et\u00a0al (2020) Fracture risk following high-trauma versus low-trauma fracture: a\u00a0registry-based cohort study. Osteoporos Int 31(6):1059\u20131067. https:\/\/doi.org\/10.1007\/s00198-019-05274-2","journal-title":"Osteoporos Int"},{"issue":"6","key":"1884_CR17","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1503\/cmaj.070234","volume":"177","author":"A Cranney","year":"2007","unstructured":"Cranney\u00a0A, Jamal\u00a0SA, Tsang\u00a0JF, Josse\u00a0RG, Leslie\u00a0WD (2007) Low bone mineral density and fracture burden in postmenopausal women. CMAJ 177(6):575\u2013580","journal-title":"CMAJ"},{"issue":"8","key":"1884_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1359\/jbmr.1998.13.8.1337","volume":"13","author":"KM Sanders","year":"1998","unstructured":"Sanders\u00a0KM, Pasco\u00a0JA, Ugoni\u00a0AM, Nicholson\u00a0GC, Seeman\u00a0E, Martin\u00a0TJ et\u00a0al (1998) The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community: the Geelong osteoporosis study. J\u00a0Bone Miner Res 13(8):1337\u20131342","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1884_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1055\/s-0038-1673537","volume":"27","author":"F Thomasius","year":"2018","unstructured":"Thomasius\u00a0F, Baum\u00a0E, Bernecker\u00a0P, B\u00f6cker\u00a0W, Brabant\u00a0T, Clarenz\u00a0P et\u00a0al (2018) S\u20113 DVO guidelines 2017 in prophylaxis, diagnosis and therapy of osteoporosis in postmenopausal women und men. Osteologie 27(3):154\u2013160. https:\/\/doi.org\/10.1055\/s-0038-1673537","journal-title":"Osteologie"},{"issue":"8","key":"1884_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis\u00a0JA, Oden\u00a0A, Johnell\u00a0O, Johansson\u00a0H, De Laet\u00a0C, Brown\u00a0J et\u00a0al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033\u20131046. https:\/\/doi.org\/10.1007\/s00198-007-0343-y","journal-title":"Osteoporos Int"},{"issue":"6","key":"1884_CR21","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1172\/JCI113523","volume":"81","author":"SL Hui","year":"1988","unstructured":"Hui\u00a0SL, Slemenda\u00a0CW, Johnston\u00a0CC (1988) Age and bone mass as predictors of fracture in a\u00a0prospective study. J\u00a0Clin Invest 81(6):1804\u20131809","journal-title":"J Clin Invest"},{"issue":"12","key":"1884_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"JA Kanis","year":"2001","unstructured":"Kanis\u00a0JA, Johnell\u00a0O, Oden\u00a0A, Dawson\u00a0A, De Laet\u00a0C, Jonsson\u00a0B (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12(12):989\u2013995. https:\/\/doi.org\/10.1007\/s001980170006","journal-title":"Osteoporos Int"},{"issue":"2","key":"1884_CR23","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1007\/s00198-004-1702-6","volume":"16","author":"O Johnell","year":"2005","unstructured":"Johnell\u00a0O, Kanis\u00a0J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(2):S3\u20137. https:\/\/doi.org\/10.1007\/s00198-004-1702-6","journal-title":"Osteoporos Int"},{"key":"1884_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-013-0136-1","author":"E Hernlund","year":"2013","unstructured":"Hernlund\u00a0E, Svedbom\u00a0A, Iverg\u00e5rd\u00a0M, Compston\u00a0J, Cooper\u00a0C, Stenmark\u00a0J et\u00a0al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A\u00a0report prepared in collaboration with the international osteoporosis foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA). Arch Osteoporos. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"issue":"1","key":"1884_CR25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/ard.2008.092775","volume":"68","author":"TACM van Geel","year":"2009","unstructured":"van Geel\u00a0TACM, van Helden\u00a0S, Geusens\u00a0PP, Winkens\u00a0B, Dinant\u00a0GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68(1):99\u2013102","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1884_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00404-021-06123-6","volume":"304","author":"P Hadji","year":"2021","unstructured":"Hadji\u00a0P, Schweikert\u00a0B, Kloppmann\u00a0E, Gille\u00a0P, Joeres\u00a0L, Toth\u00a0E et\u00a0al (2021) Osteoporotic fractures and subsequent fractures: imminent fracture risk from an analysis of German real-world claims data. Arch Gynecol Obstet 304(3):703\u2013712","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"1884_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s00198-003-1516-y","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis\u00a0JA, Oden\u00a0A, Johnell\u00a0O, De Laet\u00a0C, Jonsson\u00a0B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108\u2013112","journal-title":"Osteoporos Int"},{"issue":"18","key":"1884_CR28","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles\u00a0KW et\u00a0al (2007) N\u00a0Engl J Med 357(18):1799\u20131809","journal-title":"N Engl J Med"},{"issue":"5","key":"1884_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/jbmr.3958","volume":"35","author":"MS LeBoff","year":"2020","unstructured":"LeBoff\u00a0MS, Chou\u00a0SH, Murata\u00a0EM, Donlon\u00a0CM, Cook\u00a0NR, Mora\u00a0S et\u00a0al (2020) Effects of supplemental vitamin\u00a0D on bone health outcomes in women and men in the VITamin D and OmegA\u20113 TriaL (VITAL). J\u00a0Bone Miner Res 35(5):883\u2013893","journal-title":"J Bone Miner Res"},{"issue":"10117","key":"1884_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler\u00a0DL, Marin\u00a0F, Zerbini\u00a0CAF, Russo\u00a0LA, Greenspan\u00a0SL, Zikan\u00a0V et\u00a0al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a\u00a0multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240","journal-title":"Lancet"},{"issue":"15","key":"1884_CR31","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag\u00a0KG, Petersen\u00a0J, Brandi\u00a0ML, Karaplis\u00a0AC, Lorentzon\u00a0M, Thomas\u00a0T et\u00a0al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N\u00a0Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"9999","key":"1884_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder\u00a0BZ, Tsai\u00a0JN, Uihlein\u00a0AV, Wallace\u00a0PM, Lee\u00a0H, Neer\u00a0RM et\u00a0al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a\u00a0randomised controlled trial. Lancet 386(9999):1147\u20131155","journal-title":"Lancet"},{"key":"1884_CR33","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz163","author":"SK Ramchand","year":"2020","unstructured":"Ramchand\u00a0SK, David\u00a0NL, Leder\u00a0BZ, Tsai\u00a0JN (2020) Bone mineral density response with denosumab in combination with standard or high-dose teriparatide: the DATA-HD RCT. J\u00a0Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz163","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1884_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","volume":"7","author":"JN Tsai","year":"2019","unstructured":"Tsai\u00a0JN, Lee\u00a0H, David\u00a0NL, Eastell\u00a0R, Leder\u00a0BZ (2019) Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a\u00a0randomised, controlled phase\u00a04\u00a0trial. Lancet Diabetes Endocrinol 7(10):767\u2013775","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1884_CR35","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/endrev\/bnab028","volume":"43","author":"PR Ebeling","year":"2022","unstructured":"Ebeling\u00a0PR, Nguyen\u00a0HH, Aleksova\u00a0J, Vincent\u00a0AJ, Wong\u00a0P, Milat\u00a0F (2022) Secondary osteoporosis. Endocr Rev 43(2):240\u2013313","journal-title":"Endocr Rev"},{"issue":"1","key":"1884_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis\u00a0JA, Norton\u00a0N, Harvey\u00a0NC, Jacobson\u00a0T, Johansson\u00a0H, Lorentzon\u00a0M et\u00a0al (2021) SCOPE 2021: a\u00a0new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82","journal-title":"Arch Osteoporos"},{"issue":"2","key":"1884_CR37","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00198-020-05557-z","volume":"32","author":"E McCloskey","year":"2021","unstructured":"McCloskey\u00a0E, Rathi\u00a0J, Heijmans\u00a0S, Blagden\u00a0M, Cortet\u00a0B, Czerwinski\u00a0E et\u00a0al (2021) The osteoporosis treatment gap in patients at risk of fracture in European primary care: a\u00a0multi-country cross-sectional observational study. Osteoporos Int 32(2):251\u2013259","journal-title":"Osteoporos Int"},{"issue":"7","key":"1884_CR38","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00198-004-1740-0","volume":"16","author":"J Alegre-L\u00f3pez","year":"2005","unstructured":"Alegre-L\u00f3pez\u00a0J, Cordero-Guevara\u00a0J, Alonso-Valdivielso\u00a0JL, Fern\u00e1ndez-Mel\u00f3n\u00a0J (2005) Factors associated with mortality and functional disability after hip fracture: an inception cohort study. Osteoporos Int 16(7):729\u2013736","journal-title":"Osteoporos Int"},{"issue":"12","key":"1884_CR39","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00198-010-1178-5","volume":"21","author":"KMB Huntjens","year":"2010","unstructured":"Huntjens\u00a0KMB, Kosar\u00a0S, van Geel\u00a0TACM, Geusens\u00a0PP, Willems\u00a0P, Kessels\u00a0A et\u00a0al (2010) Risk of subsequent fracture and mortality within 5\u00a0years after a\u00a0non-vertebral fracture. Osteoporos Int 21(12):2075\u20132082","journal-title":"Osteoporos Int"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-025-01884-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-025-01884-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T09:48:13Z","timestamp":1749203293000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-025-01884-7"}},"subtitle":["Ein Update zu aktuellen Leitlinien","An update on current guidelines"],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1884"],"URL":"https:\/\/doi.org\/10.1007\/s00108-025-01884-7","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"27 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"P.\u00a0Klemm: A.\u00a0Finanzielle Interessen: Beratungs- und Vortragshonorare und\/oder Reisekostenunterst\u00fctzung: AbbVie, AstraZeneca, BMS, Biogen, Boehringer Ingelheim, Janssen, Lilly, medac, Novartis, Pfizer, UCB. \u2013 B. Nichtfinanzielle Interessen: Sektionsleiter der Osteologie und Physikalischen Medizin des Campus Kerckhoff der Justus-Liebig-Universit\u00e4t und der Kerckhoff-Klinik, zudem Oberarzt der Rheumatologie in diesem Haus | Mitglied der Kommission Osteoporose der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie (DGRh), Mitgliedschaften: DGRh, Dachverband Osteologie (DVO). N.\u00a0Schulz: A. Finanzielle Interessen: Referent f\u00fcr die Rheumaakademie in der Fortbildung Begutachtung von Osteopathien insbesondere Osteoporose. \u2013 B. Nichtfinanzielle Interessen: Angestellter Arzt in Weiterbildung zum Rheumatologen an der Kerckhoff Klinik Bad Nauheim | \u00c4rztlicher Leiter Osteoporoseselbsthilfegruppe Bad Nauheim | Mitgliedschaft: DGRh.. U.\u00a0Lange: A. Finanzielle Interessen: U. Lange gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B. Nichtfinanzielle Interessen: Emeritiert (ehem. Professur f\u00fcr Internistische Rheumatologie, Osteologie, Physikalische Medizin, JLU Gie\u00dfen) | Mitgliedschaften: DGIM, DGPRM.. B.\u00a0B\u00fchring: A.\u00a0Finanzielle Interessen: AbbVie \u2013\u00a0Kostenerstattung, Amgen\u00a0\u2013 Honorar und Kostenerstattung, AstraZeneca \u2013\u00a0Honorar, Biogen\u00a0\u2013 Honorar und Kostenerstattung, Boehringer-Ingelheim \u2013\u00a0Honorar, Gilead\/Galapagos\/ AlfaSigma\u00a0\u2013 Honorar und Kostenerstattung, Janssen \u2013\u00a0Kostenerstattung, MSD\u00a0\u2013 Honorar, Theramex \u2013\u00a0Honorar und Kostenerstattung, Sanofi Genzyme\u00a0\u2013 Honorar, UCB \u2013\u00a0Honorar und Kostenerstattung.\u00a0\u2013 AbbVie \u2013\u00a0Berater, Alexion\u00a0\u2013 Berater, Amgen \u2013\u00a0Berater, AstraZeneca\u00a0\u2013 Berater und interner Schulungsreferent, Fresenius Kabi \u2013\u00a0Berater, Gilead\/Galapagos\/ AlfaSigma\u00a0\u2013 Berater, Theramex \u2013\u00a0Berater, UCB\u00a0\u2013 Berater. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Facharzt f\u00fcr Innere Medizin, Rheumatologie und Geriatrie, Cellitinnen-Krankhaus, Wuppertal; Sekret\u00e4r im Vorstand des Dachverbands Osteologie (DVO), Mitglied der Kommission Osteologie der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie (DGRh), Mitglied des \u201ecommittee of scientific advisors\u201c der International Osteoporosis Foundation (IOF), Mitglied des wissenschaftlichen Beirats des Bundesselbsthilfeverbands f\u00fcr Osteoporose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}